Previous close | 10.52 |
Open | 10.51 |
Bid | 10.58 x 100 |
Ask | 10.71 x 200 |
Day's range | 10.28 - 11.10 |
52-week range | 4.80 - 12.93 |
Volume | |
Avg. volume | 982,996 |
Market cap | 548.334M |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.54 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.40 |
BRISBANE, Calif., March 11, 2024--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.
CareDx ( NASDAQ:CDNA ) Full Year 2023 Results Key Financial Results Revenue: US$280.3m (down 13% from FY 2022). Net...
CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript February 28, 2024 CareDx, Inc beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.24. CDNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to CareDx, Inc. Fourth Quarter […]